

ASX RELEASE

18 December 2019

Change of Registered Office and Principal Place of Business

The Company has changed its Registered Office and Principal Place of Business to:

Level 29, 55 Collins Street, Melbourne 3000

- End -

Authorised by the Board. For further details contact:

Dr. John Lambert
Chief Executive Officer
John@ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics is a biopharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) small molecule inhibitors to address serious unmet medical needs in cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a development focus in pancreatic and ovarian cancer. FAK may also play a significant biological role in the progression of chronic fibrotic diseases, such as hepatic fibrosis and idiopathic pulmonary fibrosis (IPF).

Amplia Therapeutics is listed on the Australian Securities Exchange (ASX.ATX). For information about Amplia Therapeutics and its pipeline, please visit our website at ampliatx.com.